Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia
about
Measurable residual disease testing in acute myeloid leukaemia.Automated Assessment of Disease Progression in Acute Myeloid Leukemia by Probabilistic Analysis of Flow Cytometry Data.Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).Minimal residual disease in acute myeloid leukaemiaMRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.Advances in treating acute myeloid leukemia.Acute myeloid leukemia: 2014 update on risk-stratification and management.Technical issues: flow cytometry and rare event analysis.Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaCurrent Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCTClinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemiaMinimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.Natural killer cell therapy in children with relapsed leukemia.Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?Measurements of treatment response in childhood acute leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Automated analysis of acute myeloid leukemia minimal residual disease using a support vector machine.Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.A critical review of which children with acute myeloid leukaemia need stem cell procedures.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Advances and issues in flow cytometric detection of immunophenotypic changes and genomic rearrangements in acute pediatric leukemia.Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia.Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.Acute myeloid leukemia: 2016 Update on risk-stratification and management.How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation.The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaNew drug approvals in acute myeloid leukemia: what's the best end point?Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
P2860
Q30234914-37392055-2AD5-4150-992E-7031D2F63247Q31114708-EF102385-C62F-4FFB-B16D-5E707D131AB3Q33822055-E81B073F-4587-44A6-94AE-91BBB2F23D13Q34179265-852C3B24-F6BB-4F5A-BE94-A387DE167D72Q34227693-12F7BDD0-B5B2-425A-8565-7B1B906C73D2Q34312351-2C230E9A-F2FD-4518-9AE2-E5721392F1ADQ34665691-9FD35448-A37E-4DC4-941D-64AA44FCD19FQ34670653-BE17BA26-CFF5-4C0F-92BA-317898CE09D1Q34674124-6B0AC7A2-0C64-4CB1-AD34-7C097C83980EQ34742630-4E8D5AF0-0C05-4B8A-97E7-08681130D07DQ35546759-98587BA3-E563-47E4-9E05-6034ACB4084BQ35582360-58C14B53-EFF7-4081-8F35-DCC6FBEA3196Q35604619-20FDA0E8-76AC-4532-ACE5-0C387E4F2B37Q35992927-6A8EC78E-688D-4563-A8B3-8B5BD09C3597Q36036315-73F817E6-B467-4CA0-BAEE-8E186A072990Q36053792-F4FBB630-7280-40E6-9FCC-76768985D178Q36208652-EDB3E2AA-2D99-44DC-BF4D-55792EBAD69AQ36251948-2A557E71-6671-4B49-B383-702BD4795300Q36508284-513B860B-DB39-44D2-874F-55DBA75C21AFQ36513773-F0C250E1-4833-4D64-8F2A-65B155CA3F1CQ37624593-8F7B1234-84F4-41F8-8321-F89A282E6811Q37687740-1AFCB70D-4C61-49F2-B952-3BEFBE2296A5Q38096909-02328F47-E12B-4E16-860A-053DCCBB0094Q38105123-063A8AEA-7CD6-45F2-B86A-000D21C5118DQ38196743-73A2C7A2-B08D-4AFB-AD9E-D825C688F05AQ38205864-149883FD-29B5-48E4-BF23-CBE0E1CA9604Q38212956-6A88CFB5-955D-49C7-BD7D-5A6142E4FA87Q38263126-2E17DED4-85E5-401D-9102-C4E932FA989EQ38719359-FCB13CA7-E4A5-44A1-BE82-9E8EBCFA06AFQ38760676-D06011D0-B08C-4550-9B9C-0119B146DF0BQ38881996-767DBE3B-99A8-4D40-B04C-9C860F9F8CA0Q38897289-FEA5C540-B65B-4F34-86FF-218F38863D44Q40033118-D3F35B66-59EC-4EA7-8A83-B18E59A5C864Q40316983-64687EA0-7719-44C8-B395-E2BF11FD070BQ40370775-D09667F9-2FFD-4C0D-B65E-50B081CEAD20Q41264435-D52329D6-DD68-43A5-967D-BA824EC419FCQ42637732-03B7AFA5-A452-4DD3-86B0-146F4F64BE05Q43175202-728BDF45-5741-4705-8DA7-C07425A2073CQ43555651-0301D253-E3A3-4886-BEA0-D694BD275DF8Q45886072-B9D173C8-50BA-468E-AF33-141F71CEC960
P2860
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Comparative analysis of differ ...... onse in acute myeloid leukemia
@ast
Comparative analysis of differ ...... onse in acute myeloid leukemia
@en
type
label
Comparative analysis of differ ...... onse in acute myeloid leukemia
@ast
Comparative analysis of differ ...... onse in acute myeloid leukemia
@en
prefLabel
Comparative analysis of differ ...... onse in acute myeloid leukemia
@ast
Comparative analysis of differ ...... onse in acute myeloid leukemia
@en
P2093
P2860
P356
P1476
Comparative analysis of differ ...... onse in acute myeloid leukemia
@en
P2093
Barbara Degar
Dario Campana
Elaine Coustan-Smith
Gary V Dahl
Hiroto Inaba
James R Downing
Jeffrey E Rubnitz
Jeffrey Jacobsen
Jeffrey W Taub
Kathleen Y Wang
P2860
P304
P356
10.1200/JCO.2011.41.5323
P407
P577
2012-09-10T00:00:00Z